{
    "clinical_study": {
        "@rank": "156587", 
        "arm_group": [
            {
                "arm_group_label": "AZD 1775 (MK 1775) and gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine: 1000 mg/m2, intravenously on Days 1, 8, and 15 of every 28 day cycle.\nAZD 1775 (MK 1775): 200 mg, by mouth, once a day on Days 1, 2, 8, 9, 15, and  16 of every 28 day cycle."
            }, 
            {
                "arm_group_label": "AZD 1775 (MK 1775) placebo and gemcitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine: 1000 mg/m2, intravenously on Days 1, 8, and 15 of every 28 day cycle.\nAZD 1775 (MK 1775) placebo: by mouth, once a day on Days 1, 2, 8, 9, 15, and  16 of every 28 day cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 2 (the second phase in testing a new drug or drug combination, to see how\n      useful the drug or combination is) of chemotherapy drug, gemcitabine, when given alone or in\n      combination with investigational drug, AZD 1775 (also called MK-1775), in patients with\n      recurrent (the cancer has returned), platinum-resistant (the cancer does not respond to\n      platinum-based therapies) ovarian, peritoneal or fallopian tube cancers.\n\n      Gemcitabine is a chemotherapy drug commonly used to treat patients with recurrent,\n      platinumresistant ovarian, peritoneal or fallopian tube cancers. Gemcitabine works by\n      preventing tumor cells from multiplying by damaging their DNA, which in turn stops the tumor\n      from growing. However, a protein, called Wee1, may play a role in helping to repair damaged\n      tumor cells, so that the tumor continues to grow.\n\n      AZD 1775 (MK-1775) is a new drug which may block Wee1 protein activity. When given in\n      combination with gemcitabine, AZD 1775 (MK-1775) may help prevent the Wee1 protein from\n      repairing damaged tumor cells without causing harm to normal cells. This is believed to\n      increase the effectiveness of gemcitabine."
        }, 
        "brief_title": "A Study Comparing AZD-1775 (MK-1775) and Gemcitabine With Gemcitabine Alone in Ovarian, Peritoneal or Fallopian Tube Cancers", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Epithelial Ovarian Carcinoma", 
            "Primary Peritoneal Carcinoma", 
            "Fallopian Tube Carcinoma", 
            "Platinum-resistant", 
            "Platinum-refractory"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Fallopian Tube Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Measurable, platinum resistant/refractory epithelial ovarian, primary peritoneal or\n             fallopian-tube carcinoma\n\n          -  Any number of prior lines of therapy\n\n          -  Completed any prior chemotherapy, radiotherapy or major surgery at least 4 weeks\n             before receiving study treatment.\n\n          -  Age 18 years or older on day of consent.\n\n          -  ECOG performance status 2 or less\n\n          -  Life expectancy greater than 3 months\n\n          -  Normal organ and marrow function\n\n          -  Can tolerate oral medication and no bowel obstruction\n\n          -  Disease that is amenable to biopsy and willing to have biopsies\n\n          -  Agree to contraception, not pregnant\n\n          -  Understand and sign consent\n\n        Exclusion Criteria:\n\n          -  Previously received gemcitabine for t recurrent disease\n\n          -  Receiving other investigational agents\n\n          -  Unstable brain metastases\n\n          -  History of allergic reactions to AZD 1775 (MK-1775) or gemcitabine\n\n          -  Receiving sensitive CYP3A4 substrates, CYP3A4 substrates with a narrow therapeutic\n             index, moderate to potent inhibitors / inducers of CYP3A4.\n\n          -  Pregnant/breastfeeding\n\n          -  HIV positive on combination antiretroviral therapy\n\n          -  Uncontrolled intercurrent illness including, but not limited to, myocardial\n             infarction within 6 months, congestive heart failure, symptomatic congestive heart\n             failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular\n             arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious\n             infections, active peptic ulcer disease, active liver disease or cerebrovascular\n             disease with previous stroke, or psychiatric illness/social situations that would\n             limit compliance with study requirements"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151292", 
            "org_study_id": "PHL-093 / NCI 9568"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD 1775 (MK 1775) and gemcitabine", 
                "intervention_name": "AZD 1775 (MK 1775)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AZD 1775 (MK 1775) placebo and gemcitabine", 
                "intervention_name": "AZD 1775 (MK 1775) placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "AZD 1775 (MK 1775) and gemcitabine", 
                    "AZD 1775 (MK 1775) placebo and gemcitabine"
                ], 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AZD 1775", 
            "MK-1775", 
            "gemcitabine", 
            "capsules"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Lainie Martin, M.D.", 
                    "phone": "215-728-3889"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111-2497"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lainie Martin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Prafull Ghatage, M.D.", 
                    "phone": "(403) 521-3721"
                }, 
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Tom Baker Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Prafull Ghatage, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Hoskins, M.D.", 
                    "phone": "(604) 877-6000"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BC Cancer Agency"
                }, 
                "investigator": {
                    "last_name": "Paul Hoskins, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Holger (Hal) Hirte, M.D.", 
                    "phone": "(905) 387-9495"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Holger (Hal) Hirte, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stephen Welch, M.D.", 
                    "phone": "(519) 685-8640"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "London Regional Cancer Program"
                }, 
                "investigator": {
                    "last_name": "Stephen Welch, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Johanne Weberpals, M.D.", 
                    "phone": "(613) 737-8899", 
                    "phone_ext": "76462"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa Regional Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Johanne Weberpals, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Amit Oza, M.D.", 
                    "phone": "416-946-2818"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Amit Oza, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD1775 (MK1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers", 
        "overall_contact": {
            "last_name": "Amit Oza, M.D.", 
            "phone": "416-946-2818"
        }, 
        "overall_official": {
            "affiliation": "Princess Margaret Cancer Centre", 
            "last_name": "Amit Oza, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (in months) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151292"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in tumor size (in millimeters) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Change in levels of CA125 of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Overall survival (in months) of gemcitabine and AZD 1775 (MK 1775) compared to gemcitabine alone", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Total incidence of adverse events by event and rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Number of TP53 mutations compared to response to treatment", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Levels of p53 protein compared to response to treatment", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}